Havekes Bas, van Manen Jeannette G, Krediet Raymond T, Boeschoten Elisabeth W, Vandenbroucke Jan P, Dekker Friedo W
Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Am J Kidney Dis. 2006 May;47(5):823-9. doi: 10.1053/j.ajkd.2006.01.019.
Troponin T is a good predictor of all-cause and cardiovascular mortality in cardiac patients. Although it is known that troponin T is an independent risk factor in dialysis patients as well, its prognostic value when measured routinely in clinical practice, particularly in addition to other risk indicators, is unclear.
A cohort of 847 patients who started dialysis therapy between 1997 and 2001 and participated in a multicenter follow-up study was examined. Clinical data were determined 3 months after the start of dialysis therapy. Patients were followed up until date of death or censoring in November 2003.
For patients with troponin T values of 0.05 to 0.10 microg/L, hazard ratio for all-cause mortality was 2.2 (95% confidence interval [CI], 1.7 to 2.8) compared with patients with values less than 0.05 microg/L. For patients with values greater than 0.10 microg/L (11%), hazard ratio was 3.3 (95% CI, 2.5 to 4.5). A survival model with clinical and laboratory risk indicators yielded an area under the curve of 0.81, which did not increase when troponin T level was added to the model. The area under the curve for troponin T level alone was 0.67. No important differences were found between patients on hemodialysis or peritoneal dialysis therapy and between patients with high and low residual renal function.
Although troponin T level is an independent risk factor for mortality in dialysis patients, it has limited added predictive power as a routine screening test over other clinical risk factors in dialysis patients.
肌钙蛋白T是心脏病患者全因死亡率和心血管死亡率的良好预测指标。虽然已知肌钙蛋白T在透析患者中也是一个独立的危险因素,但其在临床实践中常规检测时的预后价值,尤其是在联合其他风险指标时,尚不清楚。
对1997年至2001年间开始透析治疗并参与一项多中心随访研究的847例患者进行了检查。在透析治疗开始3个月后确定临床数据。对患者进行随访直至2003年11月死亡或失访。
肌钙蛋白T值为0.05至0.10μg/L的患者,与肌钙蛋白T值小于0.05μg/L的患者相比,全因死亡率的风险比为2.2(95%置信区间[CI],1.7至2.8)。肌钙蛋白T值大于0.10μg/L的患者(11%),风险比为3.3(95%CI,2.5至4.5)。包含临床和实验室风险指标的生存模型的曲线下面积为0.81,在模型中加入肌钙蛋白T水平后该面积并未增加。单独肌钙蛋白T水平的曲线下面积为0.67。血液透析或腹膜透析治疗的患者之间以及残余肾功能高低的患者之间未发现重要差异。
虽然肌钙蛋白T水平是透析患者死亡率的独立危险因素,但作为常规筛查试验,与透析患者的其他临床危险因素相比,其额外的预测能力有限。